Relative Intelligence · Life Sciences Tools

How Waters (WAT) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on WAT alone. It places WAT (Waters Corporation) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where WAT stands in the market, and of the alternatives worth a closer look.
Period covered: WAT's full trading record, from November 1995 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowWAT has run far ahead of the market, rising 31.9% over the past 6 months against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. Its life sciences tool peers were far apart over the past 6 months, from ILMN (Illumina, up 102%) to DHR (Danaher, up 15.0%). Consistency ↓
- Stock or market?WAT's 23.9% gain over the past 3 months far outran its industry: the life sciences tools ETF IHI (iShares U.S. Medical Devices ETF) rose 7.5%. The S&P 500 rose 3.9%. Its life sciences tool peers did not move as one over the past 3 months: ILMN (Illumina) rose 45.1%, while TECH (Bio-Techne) rose 1.4%.
- Past 1 to 3 yearsOver the past year, WAT rose 29.0% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. Even so, WAT finished behind the S&P 500 in both 2024 and 2025. By year ↓
- Long termWAT turned $10,000 into $28,200 over the past decade, against $42,100 in the S&P 500. Growth of $10,000 ↓
- In a crashWAT fell harder than the S&P 500 in five of seven sell-offs. The Covid crash was the exception: WAT fell 25.3%, less than the S&P 500's 33.7%. Crash tests ↓
- DiversificationWAT is some diversification, but not a hedge: a correlation of 0.53 with the S&P 500 over 5 years and 0.54 with the total US market, more closely than 79% of stocks worth at least $300 million. Over 10 years, WAT's beta versus the S&P 500 was 1.01: in the S&P 500's rising months it gained 1.1 times as much as the index, and in falling months it lost 1.4 times as much. Market capture ↓
- Better options
- Popular alternatives
- MRK (Merck & Co., Inc.) earned more than WAT with less volatility over the past 5 years: 16.3% a year at 24.8% volatility, against 4.5% a year at 33.9%.
- Nearby categories and themes
- JNJ (Johnson & Johnson, pharmaceuticals) and NVS (Novartis, pharmaceuticals) earned more than WAT with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 4.5% a year at 33.9%.
- Whole market
- 1,126 of the 3,633 stocks and funds worth at least $500 million earned more than WAT with less volatility over the past 5 years, among them AAPL (Apple), GOOG (Alphabet) and MSFT (Microsoft).
How much would $10,000 in WAT have grown?
This chart tracks a hypothetical $10,000 investment in WAT over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of WAT over the same span and WAT's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in WAT at the end of September 1997 would have grown to $397,649 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of WAT, and RGEN finished highest, at $1,656,966.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 140 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of WAT; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- RGEN$2M+16,470% total · +19.3% a year
- GILD$2M+15,614% total · +19.1% a year
- DHR$777,394+7,674% total · +16.2% a year
- AMGN$526,909+5,169% total · +14.6% a year
- EXPD$460,426+4,504% total · +14.1% a year
- WAT$397,649+3,876% total · +13.5% a year
- LLY$396,376+3,864% total · +13.5% a year
- RVTY$198,041+1,880% total · +10.8% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
- MRK$82,561+726% total · +7.6% a year
From the end of September 2021 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 2,078 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of WAT; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- LLY$52,411+424% total · +39.3% a year
- GILD$25,496+155% total · +20.6% a year
- MRK$22,538+125% total · +17.6% a year
- NVS$21,146+111% total · +16.2% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- JNJ$18,849+88.5% total · +13.5% a year
- WAT$12,298+23.0% total · +4.2% a year
- A$11,334+13.3% total · +2.5% a year
- RVTY$8,929−10.7% total · −2.2% a year
- ILMN$6,943−30.6% total · −7.0% a year
WAT at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- WAT's deepest decline since it began trading in 1995 was 80.1%, from September 2000 to July 2002. It took about nine years from the low to climb back to its old high.
- WAT is trading within 1% of its all-time high.
- Over 29 full calendar years, WAT's best was 2000, when it returned 215%, and its worst was 2008, when it lost 53.6%. It lost money in nine of those years.
The company
- Market value
- $43B
- Industry
- Medical - Diagnostics & Research
- Price history from
- November 1995
Returns
- Past 1 year
- +29.0%total return
- Past 3 years
- +74.6%+20.4% a year
- Past 5 years
- +24.4%+4.5% a year
- Past 10 years
- +182%+10.9% a year
- Best calendar year
- +215%2000
- Worst calendar year
- −53.6%2008
- Losing years
- 9 of 29full calendar years
Risk
- Volatility
- 33.9%typical yearly swing, 5 years
- Sharpe ratio
- 0.30return per unit of risk, 5 years
- Worst decline ever
- −80.1%Sep 2000 to Jul 2002
- From its all-time high
- At its highwithin 1%
WAT against the whole market
Where WAT ranks among every stock and fund, and what across the market has done better.
How does WAT rank among all stocks?
This section ranks WAT on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how WAT stacks up against its peers, these rankings show where it stands in the market as a whole.
- WAT's worst decline of the past 10 years ranks in the top 12% of the 2,187 stocks worth at least $300 million, where the top fell the least.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | WAT | Rank | Standing |
|---|---|---|---|
| 1-year return | +29.0% | 999 of 3,287 | top 30% |
| 3-year return | +74.6% | 1,193 of 3,017 | top 40% |
| 5-year return | +24.4% | 1,398 of 2,893 | top 48% |
| 10-year return | +182% | 941 of 2,202 | top 43% |
| Volatility, 5 years | 33.9% | 1,053 of 2,893 | top 36% |
| Sharpe ratio, 5 years | 0.30 | 1,559 of 2,893 | bottom 47% |
| Worst decline, past 10 years | −44.3% | 269 of 2,187 | top 12% |
What has beaten WAT on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). WAT sits where the dashed lines cross. Anything in the green box above and to the left earned more than WAT with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 498 stocks and 628 ETFs worth at least $500 million sit in the green region: each earned more than WAT over the past 5 years with smaller price swings. That is 31% of the 3,633 screened.
- Among those with at least half WAT's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 27% less than WAT's 33.9%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.30 for WAT.
- Among WAT's popular alternatives, MRK is in the region. MRK earned 16.3% a year against 4.5% a year for WAT, at 24.8% volatility, 27% less than WAT's 33.9%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to WAT; faint dots are 91 more of the 1,126 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than WAT?
Investments that beat WAT over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among WAT's popular alternatives, MRK earned more than WAT with less volatility over the past 5 years: 16.3% a year at 24.8% volatility, against 4.5% a year at 33.9%.
- Looking beyond its popular alternatives, JNJ (pharmaceuticals) and NVS (pharmaceuticals) earned more than WAT with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 4.5% a year at 33.9%.
- Across the whole market, 1,126 of the 3,633 stocks and funds worth at least $500 million earned more than WAT with less volatility over the past 5 years, among them AAPL, GOOG and MSFT.
How this works
The table below lists investments that beat WAT over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks WAT's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than WAT follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than WAT's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× WAT's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than WAT's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with WAT?lower diversifies more | Expenseper year | |||
| +4.5% | 33.9% | 0.30 | −44.3% | +182% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.53 | 0.09% | |||
| Popular alternativesbest 2 shownThe investments people most often weigh against WAT. 2 of 20 passed at least one test. | |||||||||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.28 | — | ||
| Higher return, lower volatility | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.31 | — | ||
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Life Sciences Tools and the categories next to it (Biotechnology, Medical Diagnostics, Contract Research, Pharmaceuticals), plus WAT's specific themes. 24 of 84 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.26 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.28 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.28 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.29 | — | ||
EXELExelixis, Inc. · Biotechnology | Higher return, similar volatilityHigher return in most periods | +24.4% | 35.8% | 0.79 | −57.2% | +448% | 0.29 | — | |
| Higher return, similar volatilityHigher Sharpe, smaller worst decline | +8.7% | 35.7% | 0.41 | −28.7% | +257% | 0.24 | — | ||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,487 of 3,529 passed at least one test. | |||||||||
EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.59 | — | |
CIBRFirst Trust Nasdaq Cybersecurity ETF · Cybersecurity | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +14.1% | 26.1% | 0.64 | −33.9% | +454% | 0.44 | 0.58% | |
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.10 | 0.40% | ||
NHCNational HealthCare Corporation · Medical - Care Facilities | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.40 | — | |
HACKAmplify Cybersecurity ETF · Technology | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.6% | 25.8% | 0.59 | −38.7% | +373% | 0.43 | 0.60% | |
| On the frontierHigher return, similar volatilityHigher return in most periods | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.17 | — | ||
| On the frontierSimilar return, lower volatilityHigher Sharpe, smaller worst decline | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.03 | 0.09% | ||
ERIEErie Indemnity Company · Property & Casualty Insurance | Higher return, lower volatilitySmaller losses in recent crashes | +6.3% | 31.4% | 0.35 | −60.9% | +200% | 0.31 | — | |
What these numbers mean for WAT
- Annual return
- WAT returned 4.5% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $12,400. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- WAT's volatility over the past 5 years was 33.9%, about twice the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, WAT's return lands within 33.9% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- WAT's Sharpe ratio over the past 5 years was 0.30, against 0.79 for the S&P 500, so WAT earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- WAT's worst fall from a peak to a low over the past 10 years was 44.3%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 44.3% fall takes a 79.4% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, WAT's monthly returns had a correlation of 0.53 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against WAT instead: the lower it is, the more that option would diversify a WAT holding. Guide: Correlation and diversification →
Show all 1,126 stocks and funds worth at least $500 million that earned more than WAT with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with WAT | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Whole market | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.59 | — |
| 2 | CIBRFirst Trust Nasdaq Cybersecurity ETF · Cybersecurity | Whole market | +14.1% | 26.1% | 0.64 | −33.9% | +454% | 0.44 | 0.58% |
| 3 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.10 | 0.40% | |
| 4 | NHCNational HealthCare Corporation · Medical - Care Facilities | Whole market | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.40 | — |
| 5 | HACKAmplify Cybersecurity ETF · Technology | Whole market | +12.6% | 25.8% | 0.59 | −38.7% | +373% | 0.43 | 0.60% |
| 6 | Whole market | +18.5% | 28.0% | 0.75 | −38.5% | +1,168% | 0.31 | — | |
| 7 | Whole market | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.24 | — | |
| 8 | IHAKiShares Cybersecurity and Tech ETF · Technology | Whole market | +8.3% | 25.0% | 0.44 | −34.4% | — | 0.46 | 0.47% |
| 9 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.54 | 0.03% | |
| 10 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.53 | 0.03% | |
| 11 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.10 | — | |
| 12 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.36 | — | |
| 13 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.40 | — | |
| 14 | DXJWisdomTree Japan Hedged Equity Fund · International Equity | Whole market | +26.6% | 19.1% | 1.34 | −39.1% | +428% | 0.20 | 0.48% |
| 15 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.36 | 0.40% |
| 16 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.36 | — | |
| 17 | BALTInnovator Defined Wealth Shield ETF · Crypto | Whole market | +6.3% | 3.3% | 1.85 | −4.9% | — | 0.45 | 0.69% |
| 18 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.24 | — | |
| 19 | Whole market | +8.2% | 16.4% | 0.57 | −36.0% | +140% | 0.50 | 0.05% | |
| 20 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.40 | 0.18% | |
| 21 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.10 | — | |
| 22 | FLRTPacer Aristotle Pacific Floating Rate High Income ETF · Financials | Whole market | +6.0% | 2.3% | 2.55 | −21.0% | +58.0% | 0.24 | 0.60% |
| 23 | Whole market | +12.1% | 13.7% | 0.90 | −36.8% | +235% | 0.58 | 0.03% | |
| 24 | Whole market | +9.3% | 16.9% | 0.61 | −35.8% | +153% | 0.53 | 0.03% | |
| 25 | Whole market | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.28 | — | |
| 26 | Whole market | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.41 | 0.09% | |
| 27 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | 0.10 | — | |
| 28 | Whole market | +14.4% | 29.9% | 0.60 | −37.9% | +755% | 0.19 | — | |
| 29 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.60 | 0.04% | |
| 30 | FFIVF5, Inc. · Cybersecurity | Whole market | +17.1% | 30.8% | 0.67 | −54.6% | +287% | 0.32 | — |
| 31 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.32 | — | |
| 32 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.52 | 0.06% | |
| 33 | Whole market | +12.2% | 29.0% | 0.54 | −37.5% | +464% | 0.26 | — | |
| 34 | Whole market | +7.1% | 22.9% | 0.42 | −38.7% | +295% | 0.34 | — | |
| 35 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.43 | — | |
| 36 | Whole market | +11.1% | 24.2% | 0.56 | −36.7% | +204% | 0.06 | — | |
| 37 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.55 | 0.06% | |
| 38 | Whole market | +11.3% | 18.8% | 0.67 | −38.4% | +170% | 0.05 | — | |
| 39 | Whole market | +6.8% | 19.4% | 0.44 | −38.7% | +122% | 0.36 | 0.09% | |
| 40 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | 0.03 | — | |
| 41 | Whole market | +13.9% | 18.5% | 0.80 | −34.0% | +446% | 0.19 | — | |
| 42 | PJULInnovator U.S. Equity Power Buffer ETF · Broad Market | Whole market | +10.5% | 8.6% | 1.20 | −18.2% | — | 0.50 | 0.79% |
| 43 | Whole market | +8.2% | 16.1% | 0.57 | −39.0% | +211% | 0.58 | 0.20% | |
| 44 | Whole market | +14.8% | 23.6% | 0.71 | −32.8% | +625% | 0.16 | — | |
| 45 | Whole market | +9.3% | 19.2% | 0.56 | −30.1% | +344% | 0.05 | — | |
| 46 | Whole market | +11.8% | 22.6% | 0.61 | −39.2% | +118% | 0.34 | — | |
| 47 | FJANFT Vest U.S. Equity Buffer ETF - January · Multi-Asset | Whole market | +11.1% | 10.5% | 1.05 | −13.6% | — | 0.44 | 0.85% |
| 48 | Whole market | +7.5% | 18.0% | 0.50 | −37.4% | +132% | 0.27 | — | |
| 49 | Whole market | +12.4% | 20.2% | 0.68 | −32.9% | +185% | 0.25 | — | |
| 50 | Whole market | +17.9% | 26.1% | 0.76 | −37.9% | +314% | 0.36 | — | |
| 51 | Whole market | +15.8% | 24.6% | 0.72 | −30.7% | +576% | 0.12 | — | |
| 52 | Whole market | +13.1% | 22.4% | 0.67 | −34.5% | +451% | 0.41 | 0.04% | |
| 53 | Whole market | +13.3% | 30.0% | 0.57 | −39.2% | +711% | 0.10 | — | |
| 54 | Whole market | +14.7% | 17.5% | 0.87 | −34.7% | — | 0.51 | 0.26% | |
| 55 | Whole market | +7.2% | 19.2% | 0.46 | −29.0% | +68.8% | 0.29 | — | |
| 56 | Whole market | +6.7% | 21.4% | 0.41 | −37.9% | +208% | 0.36 | — | |
| 57 | Whole market | +7.6% | 26.1% | 0.41 | −37.8% | +188% | 0.04 | — | |
| 58 | Whole market | +7.5% | 11.0% | 0.71 | −13.7% | — | 0.52 | 0.35% | |
| 59 | IRMIron Mountain Incorporated · Specialty REITs | Whole market | +24.6% | 30.3% | 0.88 | −39.0% | +470% | 0.22 | — |
| 60 | CASYCasey's General Stores, Inc. · Convenience Stores | Whole market | +29.9% | 29.3% | 1.04 | −36.1% | +537% | -0.03 | — |
| 61 | Whole market | +12.0% | 18.8% | 0.70 | −30.9% | +114% | 0.15 | — | |
| 62 | Whole market | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.64 | 0.08% | |
| 63 | Whole market | +8.9% | 24.7% | 0.47 | −38.3% | +407% | 0.42 | — | |
| 64 | ATOAtmos Energy Corporation · Gas Utilities | Whole market | +14.9% | 18.4% | 0.85 | −32.9% | +194% | 0.26 | — |
| 65 | Whole market | +12.5% | 31.3% | 0.53 | −37.1% | +303% | 0.10 | — | |
| 66 | CHTChunghwa Telecom Co., Ltd. · Integrated Telecommunications | Whole market | +7.7% | 13.3% | 0.63 | −23.8% | +101% | 0.26 | — |
| 67 | SPMOInvesco S&P 500 Momentum ETF · US Momentum Equity | Whole market | +18.7% | 20.8% | 0.93 | −30.9% | +499% | 0.47 | 0.13% |
| 68 | DFIVDimensional - International Value ETF · International Equity | Whole market | +14.8% | 16.4% | 0.93 | −25.4% | — | 0.44 | 0.27% |
| 69 | Whole market | +6.5% | 20.9% | 0.41 | −34.4% | +156% | 0.13 | — | |
| 70 | AVLVAvantis U.S. Large Cap Value ETF · US Large-Cap Value | Whole market | +14.0% | 16.9% | 0.86 | −19.5% | — | 0.53 | 0.15% |
| 71 | FERFerrovial N.V. · Infrastructure | Whole market | +13.4% | 31.3% | 0.56 | −38.9% | +173% | 0.17 | — |
| 72 | Same or nearby category | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.26 | — | |
| 73 | HYGHiShares Interest Rate Hedged High Yield Bond ETF · Bonds | Whole market | +6.6% | 7.1% | 0.94 | −23.9% | +74.5% | 0.44 | 1.12% |
| 74 | HDViShares Core High Dividend ETF · US Dividend Equity | Whole market | +12.9% | 13.0% | 1.00 | −37.0% | +172% | 0.41 | 0.08% |
| 75 | NINiSource Inc · Gas Utilities | Whole market | +15.1% | 20.3% | 0.80 | −30.9% | +158% | 0.20 | — |
| 76 | WECWEC Energy Group, Inc. · Electric Utilities | Whole market | +7.2% | 19.0% | 0.46 | −32.3% | +159% | 0.26 | — |
| 77 | DFATDimensional - US Targeted Value ETF · US Small-Cap Equity | Whole market | +9.6% | 21.0% | 0.54 | −26.1% | — | 0.54 | 0.33% |
| 78 | FTSFortis Inc. · Electric Utilities | Whole market | +8.4% | 16.4% | 0.58 | −34.3% | +154% | 0.26 | — |
| 79 | Same or nearby category | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.28 | — | |
| 80 | USMViShares MSCI USA Min Vol Factor ETF · US Low-Volatility Equity | Whole market | +7.6% | 12.3% | 0.66 | −33.1% | +176% | 0.58 | 0.15% |
| 81 | Same or nearby category | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.28 | — | |
| 82 | SPHQInvesco S&P 500 Quality ETF · US Quality Equity | Whole market | +12.0% | 16.7% | 0.76 | −31.6% | +300% | 0.50 | 0.20% |
| 83 | PKGPackaging Corporation of America · Packaging | Whole market | +15.4% | 25.8% | 0.69 | −38.2% | +294% | 0.26 | — |
| 84 | AEEAmeren Corporation · Electric Utilities | Whole market | +7.9% | 19.4% | 0.49 | −29.1% | +192% | 0.24 | — |
| 85 | DTMDT Midstream, Inc. · Oil & Gas Midstream | Whole market | +24.5% | 25.2% | 1.00 | −23.6% | — | 0.23 | — |
| 86 | Same or nearby category | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.29 | — | |
| 87 | SXTSensient Technologies Corporation · Specialty Chemicals | Whole market | +9.3% | 30.3% | 0.44 | −50.6% | +133% | 0.27 | — |
| 88 | COWZPacer US Cash Cows 100 ETF · US Large-Cap Value | Whole market | +11.4% | 17.7% | 0.70 | −38.7% | — | 0.51 | 0.49% |
| 89 | EWJiShares MSCI Japan ETF · International Equity | Whole market | +9.2% | 18.8% | 0.57 | −33.1% | +132% | 0.50 | 0.49% |
| 90 | WTWWillis Towers Watson Public Limited Company · Insurance | Whole market | +6.9% | 23.9% | 0.40 | −32.9% | +187% | 0.18 | — |
| 91 | XLUState Street Utilities Select Sector SPDR ETF · Utilities Equity | Whole market | +7.8% | 17.4% | 0.52 | −36.0% | +138% | 0.26 | 0.08% |
| 92 | SDYState Street SPDR S&P Dividend ETF · US Dividend Equity | Whole market | +7.6% | 14.0% | 0.59 | −36.7% | +157% | 0.51 | 0.35% |
| 93 | VRSNVeriSign, Inc. · Internet Services | Whole market | +7.8% | 25.9% | 0.42 | −38.9% | +308% | 0.26 | — |
| 94 | BUFRFT Vest Laddered Buffer ETF · Buffered Equity | Whole market | +9.9% | 10.5% | 0.96 | −13.7% | — | 0.50 | 0.10% |
| 95 | DACDanaos Corporation · Marine Shipping | Whole market | +20.6% | 32.0% | 0.75 | −94.6% | +449% | 0.06 | — |
| 96 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.45 | — | |
| 97 | EVRGEvergy, Inc. · Electric Utilities | Whole market | +9.5% | 18.9% | 0.57 | −38.8% | +109% | 0.31 | — |
| 98 | DBEFXtrackers MSCI EAFE Hedged Equity ETF · International Equity | Whole market | +13.1% | 13.8% | 0.96 | −32.5% | +206% | 0.48 | 0.35% |
| 99 | MUSAMurphy USA Inc. · Convenience Stores | Whole market | +26.1% | 31.2% | 0.90 | −35.5% | +706% | 0.09 | — |
| 100 | IOOiShares Global 100 ETF · Global Equity | Whole market | +15.7% | 17.2% | 0.94 | −31.4% | +361% | 0.47 | 0.40% |
WAT against its popular alternatives
The investments people most often weigh against WAT, compared period by period and year by year.
How do WAT's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at WAT, which divides the map into what did better or worse on each measure.
- LLY, MRK and XBI were both more rewarding and calmer than WAT over the past 5 years, earning a higher annual return with lower volatility.
- 12 of the 20 popular alternatives earned less than WAT over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, WAT returned 4.5% a year, less than the S&P 500's 12.7%, with higher volatility (33.9% against 17.1%).
Green points earned more than WAT with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| LLY Eli Lilly and Company | +40.7% | 32.8% |
| MRK Merck & Co., Inc. | +16.3% | 24.8% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| XBI State Street SPDR S&P Biotech ETF | +4.6% | 32.5% |
| WAT This pageWaters Corporation | +4.5% | 33.9% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| A Agilent Technologies, Inc. | +2.6% | 30.6% |
| MTD Mettler-Toledo International Inc. | +2.6% | 32.5% |
| IQV IQVIA Holdings Inc. | +1.3% | 34.7% |
| QGEN Qiagen N.V. | +0.6% | 26.9% |
| RVTY Revvity, Inc. | −2.2% | 35.1% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| BRKR Bruker Corporation | −6.3% | 44.3% |
| ILMN Illumina, Inc. | −7.8% | 46.9% |
| RGEN Repligen Corporation | −7.8% | 51.3% |
| ICLR ICON Public Limited Company | −8.8% | 46.1% |
| TECH Bio-Techne Corporation | −10.2% | 39.4% |
| BIO Bio-Rad Laboratories, Inc. | −13.9% | 37.9% |
| TXG 10x Genomics, Inc. | −15.1% | 70.8% |
| AVTR Avantor, Inc. | −15.5% | 41.0% |
| SDGR Schrödinger, Inc. | −16.0% | 65.7% |
| PACB Pacific Biosciences of California, Inc. | −40.0% | 97.0% |
Has WAT consistently beaten its popular alternatives?
This section compares WAT with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than WAT helps separate lasting outperformance from a single strong stretch.
- LLY outperformed WAT in every long-term period and in all but one short-term period, the most consistent record in the group.
- Only one of the 20 popular alternatives, LLY, outperformed WAT in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- LLY and MRK earned more for the risk they took than WAT (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than WAT over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| WAT Waters Corporation (this page) | — | +4.5% | +23.9% | +31.9% | +15.9% | +29.0% | +74.6% | +24.4% | +182% | 33.9% | 0.30 | −44.3% | — | $43B | — |
| LLY QualifiedEli Lilly and Company | 4/5 short3/3 longAll-weather | +10.2% | +12.1% | +40.0% | +19.4% | +59.7% | +124% | +451% | +1,807% | 32.8% | 1.21 | −34.5% | — | $1.2T | — |
| MRK Drug Manufacturers - GeneralMerck & Co., Inc. | 2/5 short2/3 long | −0.8% | +19.9% | +28.3% | +42.2% | +76.8% | +58.3% | +113% | +241% | 24.8% | 0.74 | −43.4% | — | $366B | — |
| RVTY Medical - Diagnostics & ResearchRevvity, Inc. | 5/5 short1/3 long | +8.6% | +46.6% | +67.8% | +59.3% | +64.0% | +54.6% | −10.6% | +203% | 35.1% | 0.11 | −59.0% | — | $17B | — |
| ILMN Medical - Diagnostics & ResearchIllumina, Inc. | 5/5 short1/3 long | +12.2% | +45.1% | +102% | +99.4% | +169% | +130% | −33.3% | +93.0% | 46.9% | 0.06 | −86.2% | — | $40B | — |
| A Medical - Diagnostics & ResearchAgilent Technologies, Inc. | 4/5 short1/3 long | +7.1% | +33.1% | +43.6% | +26.4% | +22.0% | +62.1% | +13.8% | +306% | 30.6% | 0.24 | −43.2% | — | $49B | — |
| TXG Biotechnology10x Genomics, Inc. | 4/5 short1/3 long | −9.7% | +65.3% | +191% | +330% | +444% | +81.2% | −55.8% | — | 70.8% | 0.12 | −96.5% | — | $9.3B | — |
| IQV Medical - Diagnostics & ResearchIQVIA Holdings Inc. | 3/5 short1/3 long | −0.8% | +31.4% | +51.5% | +18.8% | +26.3% | +45.3% | +6.5% | +260% | 34.7% | 0.21 | −51.5% | — | $44B | — |
| MTD Medical - Diagnostics & ResearchMettler-Toledo International Inc. | 2/5 short1/3 long | +14.2% | +28.3% | +23.4% | +15.8% | +20.4% | +60.2% | +13.7% | +298% | 32.5% | 0.24 | −43.5% | — | $33B | — |
| XBI HealthcareState Street SPDR S&P Biotech ETF | 2/5 short1/3 long | −3.2% | +1.5% | +11.3% | +26.2% | +39.7% | +130% | +25.1% | +159% | 32.5% | 0.30 | −63.9% | 0.35% | $10B | — |
| RGEN Medical - Instruments & SuppliesRepligen Corporation | 1/5 short1/3 long | −1.0% | +22.9% | +35.5% | +8.8% | +15.8% | +22.5% | −33.3% | +514% | 51.3% | 0.10 | −68.3% | — | $11B | — |
| TMO Medical - Diagnostics & ResearchThermo Fisher Scientific Inc. | 1/5 short1/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| TECH BiotechnologyBio-Techne Corporation | 1/5 short1/3 long | +0.2% | +1.4% | +20.2% | +22.2% | +16.7% | +15.1% | −41.4% | +191% | 39.4% | -0.08 | −67.2% | — | $11B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 0/5 short1/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| AVTR Medical - Instruments & SuppliesAvantor, Inc. | 4/5 short0/3 long | +10.1% | +55.9% | +95.5% | +45.0% | +9.5% | −19.1% | −56.9% | — | 41.0% | -0.20 | −83.2% | — | $11B | — |
| BRKR Medical - DevicesBruker Corporation | 3/5 short0/3 long | −9.2% | −0.3% | +36.3% | +16.6% | +47.4% | −5.0% | −27.7% | +171% | 44.3% | 0.08 | −68.7% | — | $8.5B | — |
| SDGR Software - ApplicationSchrödinger, Inc. | 3/5 short0/3 long | −22.6% | +56.0% | +82.8% | +30.1% | +6.5% | +6.5% | −58.2% | — | 65.7% | 0.06 | −90.2% | — | $1.8B | — |
| PACB Medical - DevicesPacific Biosciences of California, Inc. | 2/5 short0/3 long | +44.1% | +44.1% | +12.6% | +6.5% | −1.0% | −73.5% | −92.2% | −77.9% | 97.0% | -0.04 | −98.2% | — | $609M | — |
| QGEN Medical - Diagnostics & ResearchQiagen N.V. | 1/5 short0/3 long | +9.2% | +20.8% | +20.2% | +8.7% | +6.3% | +45.9% | +3.0% | +111% | 26.9% | 0.15 | −41.4% | — | $10B | — |
| ICLR Medical - Diagnostics & ResearchICON Public Limited Company | 1/5 short0/3 long | +2.7% | +4.8% | +48.7% | −7.7% | −7.6% | −23.2% | −37.0% | +106% | 46.1% | 0.04 | −76.9% | — | $13B | — |
| BIO Medical - DevicesBio-Rad Laboratories, Inc. | 0/5 short0/3 long | −6.0% | +17.4% | +16.9% | +16.1% | +10.1% | +14.1% | −52.5% | +115% | 37.9% | -0.21 | −73.8% | — | $9.5B | — |
How did WAT do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where WAT ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with WAT and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- WAT finished ahead of the S&P 500 in 15 of its 29 full calendar years, and behind it in each of the last three.
- Ranked against its popular alternatives each year, WAT finished in the top quarter in eight of 29 years and in the bottom quarter in five. In 2025, it ranked 10 of 21.
- Among its popular alternatives, IQV came out ahead of WAT most often, in eight of the 12 years both traded.
Newest year first. Green marks a year in which the fund came out ahead of WAT; gray means the two finished within a fraction of a point. The rank row places WAT among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of WAT | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WAT This pageWaters Corporation | — | +2.4% | +12.7% | −3.9% | −8.1% | +50.6% | +5.9% | +23.9% | −2.4% | +43.8% | −0.1% | +19.4% | +12.7% | +14.8% | +17.6% | −4.7% | +25.4% | +69.1% | −53.6% | +61.5% | +29.5% | −19.2% | +41.1% | +52.3% | −43.8% | −53.6% | +215% | +21.5% | +129% | +25.6% |
| Rank among alternatives | Top quarter in 8 of 29 | 10 of 21 | 2 of 21 | 14 of 21 | 4 of 21 | 6 of 21 | 19 of 20 | 13 of 18 | 14 of 18 | 7 of 18 | 11 of 18 | 7 of 18 | 11 of 18 | 16 of 17 | 13 of 17 | 7 of 17 | 7 of 16 | 3 of 16 | 14 of 16 | 4 of 16 | 8 of 15 | 15 of 15 | 1 of 15 | 6 of 15 | 11 of 15 | 15 of 15 | 1 of 13 | 6 of 12 | 1 of 11 | 6 of 10 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 14 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| LLY Eli Lilly and Company | 16 of 29 | +40.3% | +33.3% | +60.9% | +34.3% | +66.1% | +31.0% | +16.2% | +40.5% | +17.8% | −10.4% | +25.4% | +39.8% | +7.3% | +24.2% | +25.2% | +3.6% | −6.2% | −21.3% | +5.7% | −5.2% | +2.6% | −17.6% | +13.1% | −17.6% | −14.4% | +41.9% | −24.3% | +29.1% | +93.6% |
| MRK Merck & Co., Inc. | 14 of 29 | +9.8% | −6.3% | +1.0% | +49.4% | +1.8% | −7.2% | +22.3% | +40.0% | −1.5% | +15.0% | −3.9% | +16.9% | +26.9% | +13.1% | +9.6% | +2.9% | +26.7% | −45.3% | +37.3% | +42.8% | +4.0% | −27.7% | −11.2% | −1.2% | −36.0% | +41.8% | −7.7% | +41.6% | +35.7% |
| RVTY Revvity, Inc. | 11 of 29 | −13.1% | +2.4% | −21.9% | −30.1% | +40.4% | +48.2% | +24.0% | +7.8% | +40.8% | −2.1% | +23.2% | +6.8% | +31.0% | +60.4% | −21.6% | +27.1% | +50.6% | −45.9% | +18.4% | −4.5% | +6.2% | +33.9% | +112% | −75.7% | −32.7% | +154% | +52.5% | +36.6% | +6.4% |
| ILMN Illumina, Inc. | 12 of 25 | −1.8% | −1.3% | −31.1% | −46.9% | +2.8% | +11.5% | +10.6% | +37.3% | +70.7% | −33.3% | +4.0% | +66.9% | +99.0% | +82.4% | −51.9% | +106% | +17.8% | −12.1% | +50.8% | +179% | +48.6% | +34.4% | +109% | −71.3% | −26.9% | — | — | — | — |
| A Agilent Technologies, Inc. | 14 of 26 | +1.9% | −2.7% | −6.4% | −5.5% | +35.5% | +39.8% | +27.5% | +1.7% | +48.3% | +10.2% | +3.5% | +0.8% | +41.1% | +18.4% | −15.7% | +33.4% | +98.7% | −57.4% | +5.4% | +11.1% | +38.1% | −17.6% | +62.8% | −37.0% | −47.9% | −29.2% | — | — | — |
| TXG 10x Genomics, Inc. | 3 of 6 | +13.6% | −74.3% | +53.6% | −75.5% | +5.2% | +85.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| IQV IQVIA Holdings Inc. | 8 of 12 | +14.7% | −15.1% | +12.9% | −27.4% | +57.5% | +16.0% | +33.0% | +18.7% | +28.7% | +10.8% | +16.6% | +27.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| MTD Mettler-Toledo International Inc. | 16 of 28 | +13.9% | +0.9% | −16.1% | −14.8% | +48.9% | +43.7% | +40.3% | −8.7% | +48.0% | +23.4% | +12.1% | +24.7% | +25.5% | +30.9% | −2.3% | +44.0% | +55.8% | −40.8% | +44.3% | +42.8% | +7.6% | +21.6% | +31.7% | −38.2% | −4.7% | +42.4% | +36.1% | +62.7% | — |
| XBI State Street SPDR S&P Biotech ETF | 9 of 19 | +35.9% | +1.0% | +7.6% | −25.9% | −20.4% | +48.3% | +32.6% | −15.3% | +43.8% | −15.4% | +13.6% | +45.0% | +48.4% | +32.7% | +5.2% | +17.6% | +0.4% | −8.5% | +29.1% | — | — | — | — | — | — | — | — | — | — |
| RGEN Repligen Corporation | 16 of 29 | +13.8% | −20.0% | +6.2% | −36.1% | +38.2% | +107% | +75.4% | +45.4% | +17.7% | +8.9% | +42.9% | +45.2% | +117% | +81.0% | −26.0% | +14.1% | +8.7% | −42.3% | +133% | −29.8% | +38.9% | −34.1% | +43.8% | +25.1% | −28.1% | +8.0% | +145% | +63.8% | −34.4% |
| TMO Thermo Fisher Scientific Inc. | 12 of 29 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% | −11.4% | −61.5% | +6.7% |
| TECH Bio-Techne Corporation | 13 of 29 | −17.9% | −6.3% | −6.5% | −35.7% | +63.4% | +45.4% | +52.7% | +12.6% | +27.5% | +15.8% | −1.3% | −1.1% | +40.9% | +1.9% | +5.5% | −2.5% | +8.0% | −1.9% | +19.2% | −1.2% | +44.3% | +2.8% | +32.5% | −22.4% | +2.0% | +31.1% | +160% | +20.9% | +33.8% |
| DHR Danaher Corporation | 13 of 29 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% | −11.0% | +72.4% | +35.2% |
| AVTR Avantor, Inc. | 2 of 6 | −45.6% | −7.7% | +8.3% | −50.0% | +49.7% | +55.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BRKR Bruker Corporation | 14 of 25 | −19.3% | −20.0% | +7.8% | −18.3% | +55.3% | +6.6% | +71.8% | −12.8% | +62.7% | −12.2% | +23.7% | −0.8% | +29.8% | +22.7% | −25.2% | +37.7% | +199% | −69.7% | +77.1% | +54.5% | +20.7% | −11.5% | −6.4% | −70.3% | −30.6% | — | — | — | — |
| SDGR Schrödinger, Inc. | 1 of 5 | −7.3% | −46.1% | +91.5% | −46.3% | −56.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 6 of 15 | +2.2% | −81.3% | +19.9% | −60.0% | −21.1% | +405% | −30.5% | +180% | −30.5% | −71.1% | +67.5% | +49.9% | +208% | −39.3% | −82.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| QGEN Qiagen N.V. | 12 of 29 | +12.5% | +2.6% | −12.9% | −10.3% | +5.2% | +56.4% | −1.9% | +11.4% | +10.7% | +1.3% | +17.8% | −1.5% | +31.2% | +31.4% | −29.3% | −12.4% | +27.1% | −16.5% | +39.1% | +28.8% | +7.3% | −8.5% | +131% | −72.1% | −46.3% | +83.3% | +150% | +35.3% | +73.4% |
| ICLR ICON Public Limited Company | 17 of 27 | −13.1% | −25.9% | +45.7% | −37.3% | +58.8% | +13.2% | +33.3% | +15.2% | +49.1% | −3.2% | +52.4% | +26.2% | +45.6% | +62.2% | −21.9% | +0.8% | +10.4% | −36.3% | +64.1% | +83.2% | +7.2% | −11.9% | +62.0% | −9.7% | +74.1% | +0.7% | −49.3% | — | — |
| BIO Bio-Rad Laboratories, Inc. | 8 of 29 | −7.8% | +1.7% | −23.2% | −44.4% | +29.6% | +57.5% | +59.4% | −2.7% | +30.9% | +31.5% | +15.0% | −2.5% | +17.7% | +9.4% | −7.5% | +7.7% | +28.1% | −27.3% | +25.6% | +26.1% | +14.1% | −0.5% | +49.0% | +22.3% | +99.1% | +36.0% | +11.3% | −19.6% | −12.9% |
Risk and diversification
How WAT has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were WAT's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents WAT's five deepest drawdowns since it began trading in 1995, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all five of WAT's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: WAT fell 44.3% from September 2021 to October 2023, while the S&P 500 slipped only 4.7%.
- The slowest recovery came after WAT fell 80.1% from September 2000 to July 2002; it did not regain that peak until April 2011, nine years later.
Green means WAT fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | WAT fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −80.1% | −42.0% | Sep 2000 | Jul 2002 | 22 months | Apr 2011 | 8.8 years |
| 2022 bear market | −44.3% | −4.7% | Sep 2021 | Oct 2023 | 2.1 years | Sep 2026 | 2.9 years |
| Covid crash | −35.9% | −21.2% | Apr 2019 | Mar 2020 | 11 months | Jan 2021 | 10 months |
| No named crash | −35.1% | +5.9% | Sep 1999 | Dec 1999 | 3 months | Jan 2000 | 1 month |
| No named crash | −29.4% | +10.7% | Oct 1996 | Apr 1997 | 6 months | Jun 1997 | 2 months |
How did WAT do in stock market crashes?
This section measures how far WAT, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- WAT fell further than the S&P 500 in seven of the ten crashes it has traded through. The clearest case was the dot-com bust, when WAT fell 80.1% and the S&P 500 fell 47.5%.
- Among its popular alternatives, LLY held up best, falling less than WAT in nine of the ten crashes they both traded through.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than WAT.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WAT This pageWaters Corporation | — | −1.6% | −26.3% | −25.3% | −14.7% | −9.7% | −16.6% | −26.4% | −3.4% | −60.7% | −80.1% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 7 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| LLY Eli Lilly and Company | 9 of 10 | −0.6% | −11.7% | −16.9% | −10.2% | −8.6% | −19.6% | −10.9% | 0.0% | −50.0% | −54.3% |
| MRK Merck & Co., Inc. | 7 of 10 | −2.4% | −10.8% | −19.3% | −9.7% | −6.6% | −18.2% | −17.4% | −2.3% | −63.3% | −57.5% |
| RVTY Revvity, Inc. | 1 of 10 | −3.2% | −38.1% | −29.3% | −26.1% | −7.7% | −23.6% | −31.2% | −3.4% | −62.6% | −91.6% |
| ILMN Illumina, Inc. | 3 of 9 | −6.7% | −58.2% | −31.0% | −25.8% | −5.3% | −36.1% | −48.7% | −1.9% | −57.9% | — |
| A Agilent Technologies, Inc. | 2 of 10 | −3.7% | −25.3% | −25.8% | −16.1% | −8.7% | −17.6% | −37.3% | −4.2% | −67.6% | −92.4% |
| TXG 10x Genomics, Inc. | 0 of 3 | −8.1% | −81.1% | −43.1% | — | — | — | — | — | — | — |
| IQV IQVIA Holdings Inc. | 1 of 6 | −6.8% | −35.9% | −48.9% | −19.2% | −5.3% | −28.7% | — | — | — | — |
| MTD Mettler-Toledo International Inc. | 3 of 10 | −3.8% | −33.9% | −23.8% | −17.7% | −10.0% | −16.9% | −21.5% | −4.3% | −60.6% | −53.7% |
| XBI State Street SPDR S&P Biotech ETF | 2 of 9 | −6.9% | −43.6% | −32.9% | −32.5% | −5.5% | −42.6% | −26.7% | −4.1% | −37.5% | — |
| RGEN Repligen Corporation | 4 of 10 | −4.9% | −38.7% | −22.2% | −29.9% | −8.6% | −44.4% | −17.1% | −3.7% | −51.9% | −90.7% |
| TMO Thermo Fisher Scientific Inc. | 6 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| TECH Bio-Techne Corporation | 6 of 10 | −3.6% | −39.6% | −23.5% | −34.8% | −4.5% | −24.9% | −18.8% | −0.4% | −43.8% | −69.6% |
| DHR Danaher Corporation | 7 of 10 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| AVTR Avantor, Inc. | 0 of 3 | −6.2% | −50.5% | −53.9% | — | — | — | — | — | — | — |
| BRKR Bruker Corporation | 0 of 9 | −2.5% | −38.0% | −36.2% | −24.1% | −13.4% | −19.9% | −39.0% | −5.5% | −80.2% | — |
| SDGR Schrödinger, Inc. | 0 of 3 | −7.6% | −40.8% | −45.4% | — | — | — | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 0 of 7 | −6.7% | −79.3% | −47.4% | −28.1% | −10.0% | −34.7% | −75.2% | — | — | — |
| QGEN Qiagen N.V. | 8 of 10 | −0.4% | −21.3% | −12.4% | −14.0% | −7.0% | −27.8% | −25.9% | −2.6% | −45.1% | −92.1% |
| ICLR ICON Public Limited Company | 2 of 10 | −7.4% | −39.2% | −34.6% | −22.4% | −2.9% | −23.3% | −30.4% | −4.3% | −63.7% | −60.6% |
| BIO Bio-Rad Laboratories, Inc. | 6 of 10 | −1.9% | −45.3% | −21.8% | −29.7% | −8.0% | −18.1% | −25.4% | −0.5% | −50.9% | −29.1% |
How closely does WAT move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares WAT with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- LLY took just 6% of the S&P 500's losses, against 139% for WAT, while still keeping 101% of its gains.
- Over the past 10 years, WAT captured 107% of the S&P 500's gains in rising months and 139% of its losses in falling months, with a beta of 1.01. It amplified the market's moves in both directions.
- Seven of the 17 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than WAT's 0.77, led by LLY, MRK and RGEN.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than WAT's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| WAT This pageWaters Corporation | 107% | 139% | 0.77 | 1.01 |
| LLY Eli Lilly and Company | 101% | 6% | 15.73 | 0.37 |
| MRK Merck & Co., Inc. | 64% | 46% | 1.39 | 0.30 |
| RGEN Repligen Corporation | 119% | 108% | 1.11 | 0.99 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| A Agilent Technologies, Inc. | 120% | 141% | 0.85 | 1.13 |
| MTD Mettler-Toledo International Inc. | 118% | 143% | 0.83 | 1.13 |
| IQV IQVIA Holdings Inc. | 128% | 167% | 0.77 | 1.31 |
| RVTY Revvity, Inc. | 111% | 146% | 0.76 | 1.10 |
| XBI State Street SPDR S&P Biotech ETF | 93% | 122% | 0.76 | 1.01 |
| BRKR Bruker Corporation | 121% | 160% | 0.75 | 1.27 |
| QGEN Qiagen N.V. | 62% | 83% | 0.75 | 0.45 |
| TECH Bio-Techne Corporation | 120% | 162% | 0.74 | 1.23 |
| ICLR ICON Public Limited Company | 97% | 135% | 0.71 | 1.04 |
| BIO Bio-Rad Laboratories, Inc. | 104% | 146% | 0.71 | 0.99 |
| ILMN Illumina, Inc. | 120% | 200% | 0.60 | 1.19 |
| PACB Pacific Biosciences of California, Inc. | 76% | 234% | 0.33 | 1.70 |
What diversifies WAT?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with WAT's. Because such investments tend not to fall at the same time, pairing WAT with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in WAT into GLD would have cut the portfolio's volatility by 18% over the past 5 years and raised its annual return (+4.2% for WAT alone, +8.0% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of WAT over the past 5 years, with correlations of 0.36 or lower, and each still earned a positive 5-year return.
- FIX made money in six of the nine calendar years in which WAT lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which WAT lost money. The last two columns show a portfolio that is 80% WAT and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2023 | 2022 | 2018 | 2016 | 2011 | 2008 | 2005 | 2002 | 2001 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WAT Waters Corporation (this page) | 1.00 | +24.4% | 0.30 | −3.9% | −8.1% | −2.4% | −0.1% | −4.7% | −53.6% | −19.2% | −43.8% | −53.6% | 33.9% | +4.2% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.36 | +119% | 1.48 | +17.4% | +3.8% | −5.2% | — | — | — | — | — | — | 27.9% | +7.5% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.20 | +225% | 1.34 | +42.0% | +6.0% | −19.8% | +1.1% | −16.1% | −20.8% | — | — | — | 27.8% | +9.4% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.31 | +101% | 1.04 | +8.0% | +10.4% | −8.7% | +29.8% | — | — | — | — | — | 28.2% | +7.3% |
| EWP Broad MarketiShares MSCI Spain ETF | 0.39 | +140% | 0.97 | +30.3% | −5.2% | −15.3% | −1.8% | −9.8% | −36.8% | +4.6% | −13.6% | −9.2% | 28.8% | +8.2% |
| SMH TechnologyVanEck Semiconductor ETF | 0.31 | +323% | 0.97 | +73.4% | −33.5% | −9.1% | +35.6% | +6.8% | −44.7% | +10.8% | −47.0% | −14.6% | 30.0% | +11.6% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.48 | +85.0% | 0.96 | +20.1% | −5.1% | −9.5% | +6.3% | — | — | — | — | — | 28.3% | +6.8% |
| GLD CommoditiesSPDR Gold Shares | 0.10 | +126% | 0.96 | +12.7% | −0.8% | −1.9% | +8.0% | +9.6% | +4.9% | +17.8% | — | — | 27.7% | +8.0% |
| IOO InternationaliShares Global 100 ETF | 0.47 | +107% | 0.94 | +27.7% | −16.3% | −6.3% | +8.3% | −4.1% | −36.1% | +4.3% | −24.0% | −14.3% | 28.7% | +7.4% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2023 | 2022 | 2018 | 2016 | 2011 | 2008 | 2005 | 2002 | 2001 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WAT Waters Corporation (this page) | 1.00 | +24.4% | 0.30 | −3.9% | −8.1% | −2.4% | −0.1% | −4.7% | −53.6% | −19.2% | −43.8% | −53.6% | 33.9% | +4.2% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.29 | +479% | 1.55 | +34.1% | +54.1% | −24.5% | −17.5% | +8.1% | −39.6% | +18.7% | −8.3% | −2.5% | 29.1% | +11.4% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.17 | +3,143% | 1.47 | +160% | +1.3% | −16.3% | +7.4% | −24.4% | −20.5% | −25.2% | −65.1% | −25.6% | 31.3% | +23.6% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.19 | +1,636% | 1.46 | +79.6% | +17.0% | +0.8% | +18.3% | −17.0% | −15.2% | +20.1% | −9.4% | +73.7% | 30.2% | +19.8% |
| MCK Medical - DistributionMcKesson Corporation | 0.10 | +413% | 1.44 | +24.1% | +51.8% | −28.4% | −28.3% | +11.8% | −40.4% | +64.9% | −27.2% | +4.9% | 28.1% | +11.1% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.17 | +690% | 1.41 | +30.4% | +86.6% | −8.2% | +0.7% | — | — | — | — | — | 28.9% | +13.5% |
Common questions
What was WAT's worst drawdown?
WAT's deepest decline since it began trading in 1995 was 80.1%, from September 2000 to July 2002. It took about nine years from the low to climb back to its old high.
What were WAT's best and worst years?
Over 29 full calendar years, WAT's best year was 2000, when it returned 215%. Its worst was 2008, with a return of -53.6%.
Is there a better investment than WAT?
Among WAT's popular alternatives, MRK earned more than WAT with less volatility over the past 5 years: 16.3% a year at 24.8% volatility, against 4.5% a year at 33.9%. Looking beyond its popular alternatives, JNJ (pharmaceuticals) and NVS (pharmaceuticals) earned more than WAT with less volatility over the past 5 years. JNJ returned 12.7% a year at 17.9% volatility, against 4.5% a year at 33.9%.
Is WAT more volatile than the S&P 500?
Yes. WAT's volatility over the past 5 years was 33.9%, about twice the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, WAT's return lands within 33.9% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is WAT's Sharpe ratio?
WAT's Sharpe ratio over the past 5 years was 0.30, against 0.79 for the S&P 500, so WAT earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is WAT with the S&P 500?
Over the past 5 years, WAT's monthly returns had a correlation of 0.53 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against WAT instead: the lower it is, the more that option would diversify a WAT holding.
What are the best alternatives to WAT?
Of the 20 popular alternatives we compared, one outperformed WAT in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: LLY.
Did WAT outperform the S&P 500?
WAT finished ahead of the S&P 500 (SPY) in 15 of 29 full calendar years. In 2025, it returned +2.4%, against +17.7% for the index.
How did WAT do in stock market crashes?
WAT fell less than the S&P 500 (SPY) in three of the ten major crashes it has traded through, and further in seven. The clearest case was the dot-com bust, when WAT fell 80.1% and the S&P 500 fell 47.5%.
What diversifies WAT?
These had a low correlation with WAT over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.36), DXJ (correlation 0.20) and EMLP (correlation 0.31); among large stocks, CAH (correlation 0.29), CLS (correlation 0.17) and FIX (correlation 0.19). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than WAT's. Returns within 0.5 points or 3% of WAT's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.
More research
Popular alternatives to WAT
LLYEli Lilly and Company
MRKMerck & Co., Inc.
ILMNIllumina
AAgilent Technologies
IQVIQVIA
TMOThermo Fisher Scientific
DHRDanaher